Physician’s Briefing Weekly Coronavirus Roundup
Adverse Events Rare After BNT162b2 Vaccine in 5- to 11-Year-Olds
Data show 4,249 reports of adverse events after about 8.7 million doses of vaccine were administered; 97.6 percent not serious
BNT162b2 Vaccine Effectiveness 92 Percent for Teens Ages 12 to 17
Estimated vaccine effectiveness of full Pfizer-BioNTech vaccination 92 percent for preventing SARS-CoV-2 infection
Severe Illness, Viral Coinfection Common in Children With COVID-19 Hospitalization
Only one of 272 vaccine-eligible pediatric patients hospitalized with COVID-19 was fully vaccinated
ATS Issues Guidance for Managing Postprematurity Respiratory Disease
Recommendations address the outpatient management of postprematurity respiratory disease in infants, children, and adolescents
FDA May Allow Pfizer Boosters for 12- to 15-Year-Olds by Monday
Agency also expected to reduce the amount of time adolescents and adults must wait between their second dose of vaccine and booster
Global Burden of Cancer Increasing
From 2010 to 2019, largest percentage increase in numbers of cases and deaths occurred in low and middle-low SDI quintiles
Visceral Fat Tied to Arterial Stiffness in Obese Youth
Visceral fat predictive of carotid-femoral pulse wave velocity beyond body mass index and waist circumference
WMS Issues Guidelines on Tickborne Illness in the U.S.
Strong recommendations include the use of tick repellents for the skin (DEET, picaridin) and clothing (permethrin)
Genetic Diagnosis May Aid Management of Pediatric Epilepsy
Establishing a genetic diagnosis for patients with unexplained infantile or childhood-onset epilepsy can help individualize treatment
